Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29886757 | 1.00 | TLR7 (1.00) | TLR7 | |
| SCHEMBL161530 | 1.00 | TLR7 (1.00) | TLR7 | |
| SCHEMBL30575424 | 1.00 | TLR7 (1.00) | TLR7 | |
| SCHEMBL1527485 | 1.00 | TLR7 (1.00) | TLR7 | |
| SCHEMBL17874560 | 0.95 | TLR7 (0.90) | TLR7 | |
| SCHEMBL12290514 | 0.95 | TLR7 (0.90) | TLR7 | |
| SCHEMBL16284901 | 0.95 | TLR7 (0.90) | TLR7 | |
| SCHEMBL173879 | 0.94 | TLR7 (1.00) | TLR7 | |
| SCHEMBL30575433 | 0.94 | TLR7 (1.00) | TLR7 | |
| SCHEMBL12841040 | 0.93 | TLR7 (0.88) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240009215-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING SOLID TUMORS BY INTRATUMORAL ADMINISTRATION | NOVARTIS AG (CH) | 2024-01-11 | — | — | US | claimed |
| US-11752162-B2 | Compounds and compositions for treating solid tumors by intratumoral administration | NOVARTIS AG (CH) | 2023-09-12 | — | — | US | claimed |
| US-20210154214-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING SOLID TUMORS BY INTRATUMORAL ADMINISTRATION | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2021-05-27 | — | — | US | claimed |
| EP-3624806-A1 | COMPOSITIONS COMPRISING NAPHTHYRIDINE DERIVATIVES AND ALUMINIUM ADJUVANT FOR USE IN TREATING SOLID TUMORS | Novartis AG (CH) | 2020-03-25 | — | — | EP | claimed |
| WO-2018211453-A1 | COMPOSITIONS COMPRISING NAPHTHYRIDINE DERIVATIVES AND ALUMINIUM ADJUVANT FOR USE IN TREATING SOLID TUMORS | NOVARTIS AG (CH) | 2018-11-22 | — | — | WO | claimed |
| EP-2473508-B1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | NOVARTIS AG (CH) | 2017-03-08 | — | — | EP | claimed |
| US-20150225432-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | NOVARTIS AG (CH) | 2015-08-13 | — | — | US | claimed |
| US-20240009215-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING SOLID TUMORS BY INTRATUMORAL ADMINISTRATION | NOVARTIS AG (CH) | 2024-01-11 | — | — | US | disclosed |
| US-11752162-B2 | Compounds and compositions for treating solid tumors by intratumoral administration | NOVARTIS AG (CH) | 2023-09-12 | — | — | US | disclosed |
| US-11752162-B2 | Compounds and compositions for treating solid tumors by intratumoral administration | NOVARTIS AG (CH) | 2023-09-12 | — | — | US | disclosed |
| US-11752162-B2 | Compounds and compositions for treating solid tumors by intratumoral administration | NOVARTIS AG (CH) | 2023-09-12 | — | — | US | disclosed |
| US-20210154214-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING SOLID TUMORS BY INTRATUMORAL ADMINISTRATION | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2021-05-27 | — | — | US | disclosed |
| US-20210154214-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING SOLID TUMORS BY INTRATUMORAL ADMINISTRATION | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2021-05-27 | — | — | US | disclosed |
| EP-2473508-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2012-07-11 | — | — | EP | disclosed |
| WO-2012031140-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | NOVARTIS AG (CH) | 2012-03-08 | — | — | WO | disclosed |
| WO-2011049677-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011027222-A2 | IMMUNOGENIC COMPOSITIONS INCLUDING TLR ACTIVITY MODULATORS | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
| US-20110053893-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-03-03 | — | — | US | disclosed |
| US-20110053893-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-03-03 | — | — | US | disclosed |
| US-20110053893-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225432-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | TLR1, TLR6, TLR7 | TLR7 3/4885 |
| US-20210154214-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING SOLID TUMORS BY INTRATUMORAL ADMINISTRATION | TLR7, TLR9, TLR3 | TLR7 1/4885 |
| US-11752162-B2 | Compounds and compositions for treating solid tumors by intratumoral administration | TLR7, TLR9, TLR3 | TLR7 1/4885 |
| US-20110053893-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | TLR1, TLR6, TLR7 | TLR7 3/4885 |
| US-20240009215-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING SOLID TUMORS BY INTRATUMORAL ADMINISTRATION | TLR7, TLR9, TLR3 | TLR7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.